Ultragenyx Pharmaceutical (RARE) Shareholder's Equity Growth (3y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Ultragenyx Pharmaceutical | 2.29 Bn | 1.89 Bn | 106.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.34% |
| Dec 31, 2025 | -30.59% |
| Sep 30, 2025 | -73.07% |
| Jun 30, 2025 | -39.35% |
| Mar 31, 2025 | -43.45% |
| Dec 31, 2024 | -34.86% |
| Sep 30, 2024 | -28.11% |
| Jun 30, 2024 | -23.67% |
| Mar 31, 2024 | -48.95% |
| Dec 31, 2023 | -38.01% |
| Sep 30, 2023 | -63.76% |
| Jun 30, 2023 | -42.97% |
| Mar 31, 2023 | -28.73% |
| Dec 31, 2022 | -18.65% |
| Sep 30, 2022 | -13.61% |
| Jun 30, 2022 | -6.13% |
| Mar 31, 2022 | -3.52% |
| Dec 31, 2021 | 14.85% |
| Sep 30, 2021 | 12.11% |
| Jun 30, 2021 | 11.36% |
| Mar 31, 2021 | 13.37% |
| Dec 31, 2020 | 44.39% |
| Sep 30, 2020 | 22.15% |
| Jun 30, 2020 | 17.44% |
| Mar 31, 2020 | 7.64% |
| Dec 31, 2019 | 11.32% |
| Sep 30, 2019 | 16.85% |
| Jun 30, 2019 | 22.69% |
| Mar 31, 2019 | 2,028.14% |
| Dec 31, 2018 | 4.66% |
| Sep 30, 2018 | 4.73% |
| Jun 30, 2018 | 30.16% |
| Mar 31, 2018 | 28.49% |
| Dec 31, 2017 | 27.51% |
| Sep 30, 2017 | 22.40% |
| Jun 30, 2017 | 41.04% |
| Mar 31, 2017 | 43.38% |
| Dec 31, 2016 | 102.75% |